Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
…, JL Reguera-Ortega, L Camacho-Arteaga… - Blood …, 2022 - ashpublications.org
COI notes: Conflicts of Interest: GI declares having received honoraria from BMS/Celgene,
Gilead, Novartis, Janssen and Roche. KR declares having received research funding and …
Gilead, Novartis, Janssen and Roche. KR declares having received research funding and …
Efficacy and safety of opioid therapy guided by pharmacogenetics: A systematic review
…, D Comandé, L Camacho Arteaga… - …, 2021 - Future Medicine
Aim: To perform a systematic review to determine the efficacy/safety of PGx-guided opioid
therapy for chronic/postoperative pain. Materials & methods: We searched PubMed and other …
therapy for chronic/postoperative pain. Materials & methods: We searched PubMed and other …
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial
…, SO Romero, X Martinez-Gomez, L Camacho-Arteaga… - medRxiv, 2024 - medrxiv.org
The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority
phase IIb clinical trial to compare the immunogenicity and safety of a heterologous …
phase IIb clinical trial to compare the immunogenicity and safety of a heterologous …
Descripción, análisis temporal y adherencia al tratamiento de antidepresivos en atención primaria en la población mayor de 65 años de Cataluña entre 2010-2015
L Camacho-Arteaga - 2022 - ddd.uab.cat
La utilització d'antidepressius a Europa i altres llocs presenta una tendència a l'alça, amb
un major percentatge d'ús en els pacients ancians segons dades d'estudis europeus. L'…
un major percentatge d'ús en els pacients ancians segons dades d'estudis europeus. L'…
[CITATION][C] Tema 1: Diabetes tipo 2: Curso: Interacciones farmacológicas en la patología cardiovascular
R Boy, LC Arteaga - Aula de la farmacia: revista profesional de …, 2023 - dialnet.unirioja.es
[PDF][PDF] Expertos que han participado en la elaboración del protocolo ordenados
EGLR de Extremadura, ARFR de Asturias… - sanidad.gob.es
… Lina Camacho Arteaga. Representante de la Sociedad Española de Farmacología Clínica
Isabel Cano Luis. Representante de Castilla la Mancha Joan Manel Fontanet Sacristan. …
Isabel Cano Luis. Representante de Castilla la Mancha Joan Manel Fontanet Sacristan. …
[CITATION][C] Late adverse events in patients with aggressive B-cell lymphoma after CD19-targeted chimeric antigen receptor T-cell therapy
L Camacho Arteaga… - BASIC & …, 2022 - … ST, HOBOKEN 07030-5774, NJ USA
[CITATION][C] Outcomes of pregnancies exposed to methotrexate
…, L Camacho Arteaga… - BASIC & …, 2018 - … ST, HOBOKEN 07030-5774, NJ USA
[CITATION][C] Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
GI Iacoboni Garcia-Calvo - 2022 - ddd.uab.cat
… Camacho-Arteaga, Lina Fernanda (Universitat Autònoma de Barcelona. Departament de
Farmacologia, de Terapèutica i de Toxicologia) …
Farmacologia, de Terapèutica i de Toxicologia) …
Discovering event outliers for drug as commercial products
A Burinskas, A Burinskienė - 2020 - etalpykla.vilniustech.lt
On average, ten percent of drugs - commercial products are not available in pharmacies due
to shortage. The shortage event disbalance sales and requires a recovery period, which is …
to shortage. The shortage event disbalance sales and requires a recovery period, which is …
